Things are moving fast on the COVID-19 vaccine front, with the leading candidates showing impressive results in late-stage trials and two expected to be approved for use as early as next month.
On 16 November, Moderna, Inc. announced a 94.5% efficacy rate for its mRNA-1273 product in the Phase III COVE...








